title: Mycosis fungoides in a patient with ankylosing spondylitis during infliximab therapy.
abstract: Immunosuppressive therapies, in particular cyclosporine, are known to induce the development of lymphoproliferative malignancies. In general, the lymphomas that occur in the setting of impaired immune function are B cell non-Hodgkin's lymphomas, often large cell lymphomas. Mycosis fungoides (MF) is the most common form of cutaneous T cell lymphomas, which can require persistent antigen and superantigen stimulation by way of chronic immunosuppression and HIV. Tumor necrosis factor antagonists, which are novel immunomodulatory agents, might produce significant adverse effects, including an increased risk of malignancy. Currently available data do not show whether these agents were the proximate cause of the reported lymphomas. We present a 32-year-old male with ankylosing spondylitis treated with infliximab who developed MF during the second year of therapy.
authors.affiliation: Department of Dermatology, Ankara University School of Medicine, Ankara, Turkey.
authors.forename: Hatice
authors.initials: H
authors.lastname: Sanli
authors.forename: Sebnem
authors.initials: S
authors.lastname: Ataman
authors.forename: Bengü Nisa
authors.initials: BN
authors.lastname: Akay
authors.forename: Ahmet
authors.initials: A
authors.lastname: Yilmaz
authors.forename: Derya
authors.initials: D
authors.lastname: Yildizlar
authors.forename: Erbak
authors.initials: E
authors.lastname: Gürgey
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002908:Chronic Disease; D006801:Humans; D000069285:Infliximab; D008297:Male; D009182:Mycosis Fungoides / Q000139:chemically induced* / Q000175:diagnosis; D013167:Spondylitis, Ankylosing / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab